NAPLEX (North American Pharmacist Licensure Examination) Practice Exam 2026 - Free NAPLEX Practice Questions and Study Guide

Question: 1 / 1820

What is a risk of using erythropoiesis-stimulating agents (ESAs) when hemoglobin levels exceed 11 g/dL?

Decreased risk of infections

Increased risk of death

Exceeding a hemoglobin level of 11 g/dL with the use of erythropoiesis-stimulating agents (ESAs) poses a higher risk of death. This is because increasing the production of red blood cells beyond the body's natural capacity can lead to thickened blood and increased risk of blood clots, stroke, and heart attack. The other options listed are incorrect because ESAs have not been found to have any impact on reducing infection risk, reducing the need for blood transfusions or lowering the risk of hypertension. It is important to carefully monitor and adjust ESA use to avoid potential risks.

Get further explanation with Examzify DeepDiveBeta

Reduced need for blood transfusions

Lower risk of hypertension

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy